Reports Q3 revenue $734.6M, consensus $586.25M. "Our progress in the third quarter continued as we successfully expanded our COVID-19 vaccine’s label, achieved policy recommendations globally and expanded our body of clinical evidence supporting the differentiated benefit of our vaccine technology," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "New data that we announced today reaffirms the broad immune responses of NVX-CoV2373 against circulating variants. Additionally, based on our most recent Phase 1/2 trial results for our COVID-19-Influenza Combination vaccine candidate, we look forward to initiating our Phase 2 clinical trial by the end of this year."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVAX:
- Novavax (NASDAQ:NVAX) Posts Mixed Q3 Results, Revises Outlook Lower
- Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights
- Novavax options imply 18.2% move in share price post-earnings
- Novavax Earnings Are Coming; Here’s What Matters
- Novavax says data show no benefit for bivalent vaccine compared to BA.1 vaccine